International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 544-549 , June 2010

Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by β-lactam-susceptible and highly resistant pneumococci

  • Violeta Rodríguez-Cerrato

      Affiliations

    • Department of Molecular Microbiology and Infection Biology, Centro de Investigaciones Biológicas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 918 373 112x4417; fax: +34 915 360 432.
    • ,
  • Gema del Prado

      Affiliations

    • Department of Medical Microbiology and Antimicrobial Chemotherapy, Fundación Jiménez Díaz–Capio, Avenida de Reyes Católicos 2, 28040 Madrid, Spain
    • ,
  • Lorena Huelves

      Affiliations

    • Department of Medical Microbiology and Antimicrobial Chemotherapy, Fundación Jiménez Díaz–Capio, Avenida de Reyes Católicos 2, 28040 Madrid, Spain
    • ,
  • Plínio Naves

      Affiliations

    • Department of Medical Microbiology and Antimicrobial Chemotherapy, Fundación Jiménez Díaz–Capio, Avenida de Reyes Católicos 2, 28040 Madrid, Spain
    • ,
  • Vicente Ruiz

      Affiliations

    • Department of Medical Microbiology and Antimicrobial Chemotherapy, Fundación Jiménez Díaz–Capio, Avenida de Reyes Católicos 2, 28040 Madrid, Spain
    • ,
  • Ernesto García

      Affiliations

    • Department of Molecular Microbiology and Infection Biology, Centro de Investigaciones Biológicas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain
    • ,
  • Carmen Ponte

      Affiliations

    • Department of Medical Microbiology and Antimicrobial Chemotherapy, Fundación Jiménez Díaz–Capio, Avenida de Reyes Católicos 2, 28040 Madrid, Spain
    • ,
  • Francisco Soriano

      Affiliations

    • Department of Medical Microbiology and Antimicrobial Chemotherapy, Fundación Jiménez Díaz–Capio, Avenida de Reyes Católicos 2, 28040 Madrid, Spain

Received 30 November 2009 ,Accepted 10 February 2010.

References 

  1. Feikin D, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-97. Am J Public Health. 2000;90:223–229
  2. MacGowan AP. BSAC Working Parties on Resistance Surveillance. Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother. 2008;62(Suppl. 2):ii105–ii114
  3. Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2006;42:788–797
  4. World Health Organization . Pneumococcal vaccines. Wkly Epidemiol Rec. 2003;78:110–119
  5. Gombert ME, Aulicino TM. Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin. Antimicrob Agents Chemother. 1984;26:933–934
  6. Jones RN. Should novobiocin be clinically re-evaluated?. Diagn Microbiol Infect Dis. 1989;12:363–365
  7. Schmutz E, Mühlenweg A, Li S-M, Heide L. Resistance genes of aminocoumarin producers: two type II topoisomerase genes confer resistance against coumermycin A1 and clorobiocin. Antimicrob Agents Chemother. 2003;47:869–877
  8. Sugino A, Higgins NP, Brown PO, Peebles CL, Cozzarelli NR. Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc Natl Acad Sci USA. 1978;75:4838–4842
  9. Limson BM, Romansky MJ. Novobiocin, a new antibiotic; laboratory and clinical evaluation of thirty patients with bacterial pneumonia. Antibiotic Med Clin Ther. 1956;2:277–281
  10. Bridges RA, Berendes H, Good RA. Serious reactions to novobiocin. J Pediatr. 1957;50:579–585
  11. Cox RP, Foltz EL, Raymond S, Drewyer R. Novobiocin jaundice. N Engl J Med. 1959;261:139–141
  12. Nichols RL, Finland M. Novobiocin; a limited bacteriologic and clinical study of its use in forty-five patients. Antibiotic Med Clin Ther. 1956;2:241–257
  13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement Document M100-S18. Wayne, PA: CLSI; 2008.
  14. Tang JS, Gillevet PM. Reclassification of ATCC 9341 from Micrococcus luteus to Kocuria rhizophila. Int J Syst Evol Microbiol. 2003;53:995–997
  15. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004–2005. Clin Infect Dis. 2009;48:e23–33
  16. McGee L, Biek D, Ge Y, Klugman M, du Plessis M, Smith AM, et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2009;53:552–556
  17. Sá Figueiredo AM, Austrian R, Urbaskova P, Teixeira A, Tomasz A. Novel penicillin-resistant clones of Streptococcus pneumoniae in the Czech Republic and in Slovakia. Microb Drug Resist. 1995;1:71–78
  18. Soriano F, Cafini F, Aguilar L, Tarragó D, Alou L, Giménez MJ, et al. Breakthrough in penicillin resistance? Streptococcus pneumoniae isolates with penicillin/cefotaxime MICs of 16mg/L and their genotypic and geographical relatedness. J Antimicrob Chemother. 2008;62:1234–1240
  19. Arathoon EG, Hamilton JR, Hench CE, Stevens DA. Efficacy of short courses of oral novobiocin–rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates. Antimicrob Agents Chemother. 1990;34:1655–1659
  20. Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim–sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother. 1993;37:1334–1342
  21. Montecalvo MA, Horowitz H, Wormser GP, Seiter K, Carbonaro CA. Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1995;39:794
  22. Shane SH. Novobiocin, a new antibiotic. Can Med Assoc J. 1956;75:51–52
  23. Drusano GL, Townsend RJ, Walsh TJ, Forrest A, Antal EJ, Standiford HC. Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob Agents Chemother. 1986;30:42–45
  24. Welch H, Lewis CN, Putnam LE, Randall WA. A study of the sensitizing potential of novobiocin. Antibiotic Med Clin Ther. 1956;3:27–32
  25. Eder JP, Wheeler CA, Teicher BA, Schnipper LE. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res. 1991;51:510–513
  26. Soriano F, Ponte C, Nieto E, Parra A. Correlation of in-vitro activity and pharmacokinetic parameters with in-vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia. J Antimicrob Chemother. 1996;38:227–236
  27. Mandell GL, Sande MA. Penicillins, cephalosporins, and other β-lactam antibiotics. In:  Hardman J,  Limbird L,  Gilman A editor. Goodman and Gilman's the pharmacological basis of therapeutics. 7th ed.. New York, NY: Macmillan Publishing Company; 1985;p. 1115–1149
  28. Neu HC. Penicillins. In: 3rd ed..  Mandell GL,  Douglas RG,  Bennett JE editor. Principles and practice of infectious diseases. vol. 1:New York, NY: Churchill Livingstone; 1985;p. 230–250
  29. Muñoz R, Bustamante M, de la Campa AG. Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance. J Bacteriol. 1995;177:4166–4170

PII: S0924-8579(10)00081-6

doi: 10.1016/j.ijantimicag.2010.02.007

International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 544-549 , June 2010

Article Tools

* Image Usage & Resolution